Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 7/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18037988 | 0.91 | RAB9A (0.50) | DNM2HTR2CMCHR2MCHR1KMT2A | |
| SCHEMBL25858294 | 0.91 | KMT2A (0.42) | KMT2ANPC1RAB9AGBA1TP53 | |
| SCHEMBL18038014 | 0.90 | L3MBTL1 (0.50) | DNM2KMT2ANPC1RAB9ATP53 | |
| SCHEMBL18038068 | 0.89 | ALDH1A1 (0.43) | DNM2HTR2CMCHR2MCHR1BLM | |
| SCHEMBL25858229 | 0.88 | DNM2 (0.45) | DNM2HTR2CMCHR2MCHR1KMT2A | |
| SCHEMBL23258633 | 0.88 | DNM2 (0.49) | DNM2HTR2CMCHR2MCHR1KMT2A | |
| SCHEMBL25735289 | 0.87 | DNM2 (0.44) | DNM2HTR2CMCHR2MCHR1KMT2A | |
| SCHEMBL18038040 | 0.87 | RAB9A (0.48) | DNM2KMT2ARAB9AGBA1SLC2A1 | |
| SCHEMBL18037998 | 0.86 | DNM2 (0.49) | DNM2HTR2CMCHR2MCHR1NPC1 | |
| SCHEMBL23258948 | 0.86 | DNM2 (0.44) | DNM2HTR2CMCHR2MCHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321094-A1 | COMBINATION THERAPIES WITH OLIG2 INHIBITORS | Curtana Pharmaceuticals, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | DNM2 736/4885HTR2C 3524/4885MCHR2 3266/4885 |
| US-20230321094-A1 | COMBINATION THERAPIES WITH OLIG2 INHIBITORS | PAX2, GLI2, RUNX1 | DNM2 755/4885HTR2C 3440/4885MCHR2 2162/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | DNM2 736/4885HTR2C 3524/4885MCHR2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.